Business Wire

FDNA Launches Genomics Collaborative® with Multiple Research Partners Globally.


FDNA ( today announces the launch of the Genomics Collaborative ( along with multiple medical research collaborations as part of a new global initiative. Collaborators are using FDNA’s artificial intelligence and deep learning technologies to develop new precision medicine approaches for diagnosing and treating disease, and improving patients’ quality of life.

As a part of the announcement, FDNA is holding an open call for collaboration with patient advocacy groups, clinicians, labs and life sciences stakeholders.

Projects in the Genomics Collaborative are focused on using computational techniques that integrate phenotypic data into the analysis of human genetics. This process, known as “next-generation phenotyping,” or NGP, captures, structures and interprets complex physiological information.

This NGP-generated data can then be used to interpret patient genomic data to help recognize current and future health risks, as well as identify therapeutic targets that will maximize quality and length of life.

To accomplish these goals, FDNA has offered collaborators access to its technologies, which use deep learning neural networks to de-identify and analyze patients’ phenotypic information captured in images, clinical notes, and voice and video recordings to discover correlations between patient data and disease.

As part of the Genomics Collaborative launch, multiple collaborators are announcing projects and support.

Greenwood Genetic Center (GGC) in Greenwood, South Carolina has announced plans to evaluate the use of NGP in identifying and recognizing relationships between certain biomarkers and disease. One planned exploration is of the potential to correlate patterns of facial features with metabolite profiles for various genetic syndromes.

"GGC looks forward to developing new approaches to understanding our patients' health through analysis of metabolites and related genomic data," said Dr. Steve Skinner, Director of GGC. "FDNA's next-generation phenotyping technologies will support GGC in this through advanced capture and analysis of the phenotype, and use of that data to understand the patient's genome as it relates to diagnosis and care."

Dr. Andrea Superti-Furga, Head of Genetic Medicine at Lausanne University Hospital in Switzerland, is working with FDNA in the Genomics Collaborative to analyze correlations between bone structure and genomic data in hopes of yielding discoveries that will support earlier recognition and intervention for patients with skeletal dysplasia disorders.

“We are excited to analyze the characteristics of bone shape and growth for patients affected by one of the more than 400 distinct skeletal dysplasia disorders,” said Superti-Furga. “Next-generation phenotyping technologies have potential to help clinicians recognize underlying genetic or developmental problems earlier in life, allowing for more rapid diagnosis, personalized intervention and improved quality of life.”

Dr. William Dobyns at Seattle Children’s Hospital is contributing clinical data on brain abnormalities to help FDNA determine if such data correlates to genetic variations.

“FDNA has a track record of developing helpful solutions that make a real impact on patient lives,” said Dobyns, who is a medical geneticist and a pediatric neurologist. “I am pleased to help continue that tradition through contributing this data to the Genomics Collaborative.”

Bridge the Gap, an advocacy group in Cypress, Texas, is working with patients, clinicians and FDNA to study SYNGAP1 gene variants related to Fragile X, Angelman, and other related syndromes. The project aims to advance the use of facial analysis and other NGP approaches to help clinicians provide diagnosis and early personalized intervention.

The advocacy group All Things Kabuki is announcing a project to increase recognition of the Kabuki syndrome phenotype and its related gene variants. This will include facial analysis studies to enhance the capabilities already known within Face2Gene.

The successful launch of the Genomics Collaborative is credited to numerous partners, including FDNA’s Centers of Excellence in Research, which began projects with FDNA in 2017 and will continue as part of the Genomics Collaborative.

Current progress can be seen at

“The patient is our greatest asset for the future of precision medicine,” said Ilana Jacqueline, Coordinator of the Genomics Collaborative and Manager of Patient Advocacy for FDNA. “The Genomics Collaborative is making it possible to look at patients in a safe, secure way to help understand how doctors can better diagnose and treat patients, based on their unique traits.”

“We’re interested in working with others to develop technologies that easily capture and analyze that data to help health care providers have all the facts when they are evaluating patients,” Jacqueline continued, “When it comes to having the means to make a faster and more accurate diagnosis, physicians should have every advantage.”

FDNA will work with collaborators to design specific studies and securely capture and analyze patient health data that relates to the proposed research hypotheses. Data will be collected using secure portals and patient questionnaires, when applicable. Collaborators can gather and analyze a variety of data relating to the patient’s symptoms, signs, lifestyle, medical history, and genetic data.

Interested advocacy groups, clinicians, patients and researchers can visit for more information.

About the FDNA Genomics Collaborative

The Genomics Collaborative is an FDNA initiative to accelerate breakthrough in precision medicine using deep learning and artificial intelligence (AI).

Collaborators are using FDNA’s next-generation phenotyping (NGP) technologies, to analyze patient clinical data and next-generation sequencing (NGS) data. The result will be real-time discovery of disease biomarkers, advancement of clinical and molecular technologies, and big genomic data that will increase the ability of genetic testing to provide meaningful answers to difficult health questions.

About Face2Gene and FDNA

FDNA is the developer of Face2Gene* ( ), a suite of phenotyping applications that facilitates comprehensive and precise genetic evaluations. FDNA uses artificial intelligence to detect physiological patterns that reveal disease-causing genetic variations. With the world’s largest network of clinicians, labs and researchers creating one of the fastest growing and most comprehensive genomic databases, FDNA is changing the game for precision medicine.

*Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.

Contact information

Ilana Jacqueline

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Summer Business with New Shop Feature and High-Performance Tyre Models16.3.2018 17:11Tiedote

Each year, summer trade means great challenges for car garages and tyre dealers. As a result and at just the right time,, the online trade customer shop by Europe’s leading online tyre dealer Delticom, is introducing a new feature intended to make the daily work of the shop’s customers easier: An advice mode is available from now on at When changing from the purchasing to the sales view, the individual end customer prices are displayed instead of the actual purchase prices. In order to use this feature, users of simply have to insert their individual markups for the different item groups. From the markup and the purchase price, the online shop automatically calculates the personal end customer price. The usual purchasing view is also still available. This press release features multimedia. View the full release here: An advice mode immediately helps trade customers use the full pot

Available Now: The Smartphone Made for the Way We Communicate Today, the Galaxy S9 and S9+16.3.2018 15:00Tiedote

Samsung Electronics America, Inc. announced that the new, award-winning Galaxy S9 and Galaxy S9+, which have been recognized by smartphone reviewers worldwide for their best-in-class display, design and camera, are now available for purchase at U.S. wireless network providers and retail stores. The phones come in three colors: Midnight Black, Coral Blue, and the new Lilac Purple. The Galaxy S9 has a suggested retail price of $719.99, while the Galaxy S9+ is available for $839.99. Both unlocked and carrier versions of the Galaxy S9 and Galaxy S9+ are also available for purchase on This press release features multimedia. View the full release here: Designed for the way we communicate today, Samsung's new Galaxy S9 and Galaxy S9+ are available in the U.S. at wireless network providers, retailers and on (Photo: Business Wire) “The Galaxy S9 and S9+ are designed for the visual and social generation—the consum

AccelStor All-Flash Solutions Unlock Data Possibilities for AI and Cloud16.3.2018 12:00Tiedote

AccelStor, an innovative all-flash array (AFA) provider for the big data era, is excited to announce its participation in the upcoming Cloud Expo Europe, taking place from March 21 to 22 at Booth C1850 in the ExCel London exhibition centre. Besides presenting latest all-flash storage solutions breaking through performance and availability barriers for artificial intelligence (AI), virtualization and private cloud, AccelStor will present a live demonstration of its new generation NeoSapphire high availability models, one of the highlights not to be missed this year. This press release features multimedia. View the full release here: AccelStor's new generation NeoSapphire High Availability all-flash array AccelStor NeoSapphire all-flash arrays are highly integrated with virtualization and private cloud platforms, supporting VMware vSphere and OpenStack Cinder. NeoSapphire’s “high availability” series features symmetric active-activ

CONQUEST Group Announced the Expansion of its Asset Management Business with the Appointment of Philippe Taillardat to the Role of Director16.3.2018 12:00Tiedote

Philippe Taillardat brings to CONQUEST over 25 years of Asset Management and Investment Banking experience, primarily in principal investing, financial advisory, equity and debt financing across global infrastructure and sustainable energy sectors. This press release features multimedia. View the full release here: Philippe Taillardat (Photo: CONQUEST Group) Philippe was most recently Co-Head of Infrastructure Investments Europe at First State Investments, which he helped transform into one of the leading billion+ European infrastructure fund manager in core / core+ strategies. Earlier in his career, Philippe held various senior banker and investment roles at Amundi, Credit Agricole CIB, Credit Suisse, AXA and BNP Paribas. Frédéric Palanque, Managing Director of CONQUEST Group, said, "We are delighted to welcome such a recognized professional. CONQUEST is trusted for providing value-added advice in complex and highly confidential

Westinghouse Completes First Major Decommissioning Work at a Nordic Commercial Nuclear Reactor16.3.2018 11:45Tiedote

Westinghouse Electric Company announced today that it has completed a major decommissioning project at the former Barsebäck nuclear power plant in Skåne, Sweden. Barsebäck Unit 2 ceased operation in 2005 and decommissioning work began in August 2016. Westinghouse’s scope of work included the underwater segmentation and packaging of the reactor vessel internals, as well as the upfront engineering studies and equipment manufacturing and qualification. “Westinghouse is proud to deliver this major decommissioning project on time and on budget,” said Yves Brachet, Westinghouse senior vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “Our global expertise in this area will help our customers in the Nordic region to safely manage a variety of end-of-life opportunities for commercial nuclear power plants.” Leadership at Barsebäck Kraft AB (BKAB) is equally satisfied with this successful initial step of the first dismantling of a commercial nuclear power

Lighting Manufacturer LTS Licht & Leuchten, Part of the Fargerhult Group, to Offer Selected Spot- & Downlights with Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs16.3.2018 11:02Tiedote

Seoul Semiconductor, a global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs, which implement light closest to the spectrum of natural sunlight, has been adopted for selected luminaires of LTS Licht & Leuchten GmbH, a German manufacturer of high-quality luminaires for hospitality, retail, and office applications. This press release features multimedia. View the full release here: LTS Jett 100 spotlights equipped with SunLike LED technology (Photo: Business Wire) LTS has adopted SunLike natural spectrum LEDs for selected products, including the Jett 100 and CSA 60 spotlights. A series of spotlights with a discreet and individual appearance, and clear, straightforward design lines, Jett spotlights harmoniously blend in with any type of retail application. The high color rendering and superior luminous intensity of these spotlights enable lighting designers to achieve accentuated ar

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme